IVIVC in Pediatric OIPs

Transcription

1 IPAC-RS/UF Orlando Conference 2014 March 20, 2014 IVIVC in Pediatric OIPs Herbert Wachtel

2 Declaration of Conflicts of Interest H. Wachtel is employee of Boehringer Ingelheim Pharma GmbH & Co. KG, Germany. 2

3 Contents Success factors for pediatric inhalation: the inhalation device, the pharmaceutical formulation the patient (adherence ) Impactor measurements acc. to USP/Ph.Eur. vs. replica flow profiles and electronic lung introduction Comparison with in vivo deposition data literature validation Checking ped. M-T replica using monodisperse particles 3 micrometers (and below?) are our target size Applications to device and formulation development Summary 3

4 Motivation : Success factors for pediatric inhalation... (1) The inhalation device SALE Devices SALE Devices SALE Devices SALE Devices Devices SALE 4

5 Motivation : We are prepared for any challenge... (2) The pharmaceutical formulation SALE Powders for inhalation SALE Powders for inhalation SALE - toxicologically acceptable force control agents? 5

6 Motivation : We are prepared for any challenge... (3) The patient Attention Customer approaching Attention Customer approaching Attention Improper use of devices is common Design inhaler / accessory for the use with children 6

7 Summary of motivation section: - what we want to do: Make better medicines for children (~>EuPFI, US-PFI) How? Demonstrate performance in clinical trials Establish laboratory tests ( draft: <1602> Spacers and valved holding chambers ) mix Lab.- Methods and flow profile measurements -> Handling Studies low risk low cost 7

8 The aerodynamic diameter is important, but there are additional influencing factors (inhalation, airway dim. ) deposition probability ICRP-Modell shift expected for younger alveolar bronchial extrathoracic total aerodynamic diameter [µm] Source: ICRP66; 1994 International Commission of Radiological Protection + later updates H. Wachtel - PCP ad board

9 The pharmacopeial aerodynamic fine particle assessment: - lots of work but it is far away from the patient Apparatus D, 1, 3 (with presep.) Apparatus A (EP only) Q = 60 L/min Apparatus C, 4 Q = 60 L/min (and calcul.) Apparatus E, 5, 6 (with presep.) Q = L/min Q = 28.3 L/min (preferred) Apparatus 2 (USP only) Q = 60 L/min (and calcul.) 9

10 Air flow profiles for testing: important, they co-define the delivered dose, site, Example HandiHaler with flow resistance 0.16 Sqrt(mbar)*min/L Compendial testing T volume = 4 L Duration T (s) = 4 L * 60 (s/min) / Q (L/min) flow rate to achieve pressure drop = 4 kpa alternative testing volume = 1.7 L COPD (fitted avg.) (averaged?) flow profile corresponding to flow resistance of device 10

11 Performance tests closer to reality: Finlay s idealized throat models the patient. Alberta throat child s throat USP-inlet ~ The simplistic USP throat used for release testing is complemented by more realistic throat models for early development. 11

12 Realistic models of children s extrathoracic airways for in vitro inhaler testing. V= L V= L V= L V= L for comparison: adult model V=0.079 L Age 4-5 yrs Age 3-4 yrs Age 2-3 yrs Age 1-2 yrs 12

13 The in vitro patient: Upper airway model To pressurized air Inhalation device Mixing inlet Electronic lung 13

14 Minimalistic set-up for realistic inhaler tests using filters and a lung simulator Throat model e.g. Eklira Genuair Filter Breathing pattern Lung simulator ASL

15 Contents Success factors for pediatric inhalation: the inhalation device, the pharmaceutical formulation the patient Impactor measurments acc. to USP/Ph.Eur. vs. replica flow profiles and electronic lung introduction Comparison with in vivo deposition data literature validation Checking ped. replica using monodisperse particles - 3 micrometers (and below?) are our target size Applications to device and formulation development Summary 15

16 Aerosol deposition studies using our realistic pediatric models are close to published in vivo data (1)! % drug deposition related to the label claim In vivo (Wildhaber et al.*) Age 2-3 yrs In vitro (our model) Lung deposition Actuator VHC * J.H. Wildhaber et al. (1999), The Journal of Pediatrics, Vol. 135, No. 1, pp Link to scintigraphic deposition data of Wildhaber et al. (1999) in six 2 year-old children using the same pressurized Metered Dose Inhaler (albuterol) and valved holding chamber (AeroChamberPlus with facemask). 16

17 Aerosol deposition studies using our realistic pediatric models are close to published in vivo data (2)! Link to scintigraphik deposition data of Erzinger et al. (2007) in children aged 1-3 yrs using a pmdi (albuterol) and a valved holding chamber. % of drug deposition related to the label claim yrs old in vitro in vivo * Lung deposition Face Face mask don t forget the nose! * Erzinger et al. (2007), Journal of Aerosol Medicine, Vol. 20, S1, S78-84 % of drug deposition related to the label claim yrs old Lung deposition Face in vitro in vivo * Face mask 17

18 Aerosol deposition studies using realistic pediatric models are close to published in vivo data. % of drug deposition related to the label claim yrs old in vitro - oral inhalation Oral in vitro - nasal inhalation inhalation: in vivo * Lung deposition Face Face mask Nasal inhalation: Link to scintigraphic deposition data of Erzinger et al. (2007)* in children aged 1-3 yrs using a pmdi (albuterol) and a valved holding chamber. * Erzinger et al. (2007), Journal of Aerosol Medicine, Vol. 20, S1, S

19 Summary of the experimental part (1) The set up has been shown and compared to: a) pharmacopeial procedures (dose tubes, impactors) b) literature -> ( ~ Validation?) limitation: ethic considerations in children our way forward: refer to existing deposition studies clear gap: Best practice in adults: see e.g. study by Bo Olsson et al. J Aerosol Med and Pulm. Drug Delivery 26 (0), 2013, Validation of a General In Vitro Approach Recommendation: Please consider recording inhalation flow profiles when planning your next pivotal pediatric study. 19

20 Contents Success factors for pediatric inhalation: the inhalation device, the pharmaceutical formulation the patient Impactor measurments acc. to USP/Ph.Eur. vs. replica flow profiles and electronic lung introduction Comparison with in vivo deposition data literature validation Checking ped. replica using monodisperse particles 3 micrometers (and below?) are our target size Applications to device and formulation development Summary 20

21 Where do our <<inhaled>> particles go? methylene blue Inner coating: Brij + glycerol + water 21

22 Checking pediatric replica using monodisperse particles SEM image of methylene blue particle manifold & Aerosizer particles Vibrating Orifice Generator 22

23 Example: In-vitro performance with methylene blue Relevant, as children < 18 months will inhale through their nose 1-2 yrs mouth 1-2 yrs nose 100% 100% Dose to Lung [%] 80% 60% 40% 20% 3µm 5µm 7µm Dose to Lung [%] 80% 60% 40% 20% 3µm 5µm 7µm 0% 0% 15 L/min 30 L/min 60 L/min 15 L/min 30 L/min 60 L/min n.b.: typical mouth, typical nose, not from the same subject! 23

24 Example: In-vitro performance with methylene blue Partly relevant, older children will inhale through their mouth 4-5 yrs mouth 4-5 yrs nose 100% 3µm 100% 3µm Dose to Lung [%] 80% 60% 40% 20% 5µm 7µm Dose to Lung [%] 80% 60% 40% 20% 5µm 7µm 0% 0% 15 L/min 30 L/min 60 L/min 15 L/min 30 L/min 60 L/min n.b.: typical mouth, typical nose, not from the same subject! 24

25 Contents Success factors for pediatric inhalation: the inhalation device, the pharmaceutical formulation the patient Impactor measurments acc. to USP/Ph.Eur. vs. replica flow profiles and electronic lung introduction Comparison with in vivo deposition data literature validation Checking ped. replica using monodisperse particles 3 micrometers (and below?) are our target size Applications to device and formulation development Summary 25

26 Application to dry powder inhalers: Easyhaler - Novolizer & idealized child model (4-5 years) Easyhaler Novolizer drug mass (% ND) drug mass (% ND) albuterol sulfate lactose blend constant flow flow = 28, 41, 60 L/min drug mass (% ND) 100 flow profile DD throat DTL 0 DD throat DTL flow = 45, 60, 75 L/min drug mass (% ND) 0 DD throat DTL DD throat DTL PIF = 9 L/min PIF = 24, 42, 51 L/min 26

27 Formulation development: Test with lactose (34µm or 19µm) blend containing albuterol sulfate Easyhaler tube-like 4 kpa Novolizer cyclone DTL (% DD) DTL (% DD) Lactose blend 1 blend 2 34µm 19µm Easyhaler: no influence of carrier size no throat effect Novolizer: cyclone+impact+ carrier size throat effect A. Below, thesis Univ. Düsseldorf (2013) 27

28 Formulation dependence: Soft pellets do not work everywhere Amount of drug [% DD] 60 µm Throat DTL <5 µm Alberta Throat Const. Flow 4 kpa 4 L A. Below, thesis Univ. Düsseldorf (2013) 28

29 Different types of spacers / valved holding chambers lead to different throat deposition and dose to lung. % of label claim DTL 51% Throat DTL 22% DTL 33% Throat DTL 33% Throat Results using throat model and flow profiles a)single breath Respimat and b)5 breaths with spacers of a 5 year-old child. 0 RH=50% Respimat Funhaler Vortex Aerochamber Plus Mouthpiece Respimat Spacer Throat DTL Can Pediatric Throat Models and Air Flow Profiles Improve Our Dose Finding Stratety? Herbert Wachtel, Deborah Bickmann, Jorg Breitkreutz, Peter Langguth RDD 2010, Vol 1 (2010): pp

30 Focus on the patient: Very young children (below 5 years) The young child s different hardware requires adaptation! PIFA Delta Delta2 Tin T_pulse air flow rate (L/s) VA VCin inhaled volume (L) flow resistance below 5 years release 1/f time (s)

31 Handling study investigating children below 5 years: stepwise approach What is checked? Child alone With help by caregiver Valved holding chamber with help by caregiver below 5 years 31

32 In-vitro results using typical flow profiles of children -- valved holding chamber with face mask -- effect of rel. humidity r.h. years years years years 32

33 Dose prediction knowing the inhalation profile (and the inhaler/spacer+mask combination) Existing theory can be applied In-vitro calibration data Typical patient data: Resulting dosing prediction: Weight (kg) Two puffs (µg) µg/kg 10 2 x x x x (adult) 2 x

34 Summary & Conclusion Deposition studies in vitro require: Throat models Inhalation flow profiles and a common level of acceptance / standardization. -> CSA Z (Spacers + ) There is an urgent need for these tools in order to enable studies representing children of all age groups and even sub-groups immediately when devices / formulations are created. The in vitro studies contribute to a better understanding of device patient interaction and help e.g. to extend the range of applications a device might face by simplifying tests with accessories, e.g. spacers. 34

35 Many thanks to - D. Bickmann, A.-M. Ciciliani A. Jung, M. Metzger, R. Winkler: Boehringer Ingelheim - Professor Dr. Jörg Breitkreutz, A. Below: Heinrich Heine-University, Düsseldorf - Professor Dr. Peter Langguth: Johannes Guttenberg University, Mainz Herbert Wachtel Boehringer Ingelheim Pharma GmbH & Co. KG Respiratory Drug Delivery Binger Str Ingelheim am Rhein +49 (0) herbert.wachtel@boehringer-ingelheim.com 35